Beqalzi (sonrotoclax) is an oral BCL-2 inhibitor indicated to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received prior therapies, including a BTK inhibitor. Beqalzi targets the BCL-2 protein, which prevents cells from dying in a programmed fashion, and helps control disease progression in patients with advanced hematologic malignancies.

Beqalzi is a next-generation targeted therapy for the treatment of mantle cell lymphoma, and will provide a valuable option for patients with limited therapeutic options after relapse. Its approval underscores the increasing role of precision medicine in blood cancer treatment and provides new hope for better outcomes in hard-to-treat lymphoma populations.